Kidney Disease & Nephrology Clinical Trials Update: Week 17, 2026

Published April 24, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

This Phase 3 study is testing finerenone, a new oral medicine added to standard treatment, in children with chronic kidney disease and proteinuria, which means they have protein in their urine. The goal is to reduce this protein and help protect kidney health beyond current treatments. The study is recruiting children aged 6 months to under 18 years worldwide, and results are expected after about six months of treatment. This research could lead to better options for managing kidney disease in young patients.

Simultaneous Starting of the 4 Guideline Directed CKD Therapies (RAPID-CKD)

This Phase 4 trial is exploring whether starting four recommended kidney disease treatments at the same time is safe and effective for adults with chronic kidney disease and type 2 diabetes. The study aims to find a faster way to reduce kidney damage and protein in the urine without harming how the kidneys work. Conducted at a single site in the United States with 64 participants, this research could change how treatments are given to slow kidney disease progression.

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure

This Phase III trial is testing a combination of two medications, baxdrostat and dapagliflozin, in adults who have both chronic kidney disease and high blood pressure. The goal is to see if this combination can better slow the progression of kidney disease and help control blood pressure. The study involves multiple countries and adults aged 18 and older. If successful, it could offer a new treatment option for people managing these conditions together.

Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients

This completed Phase 2 trial tested thymosin alpha 1 to see if it can help prevent COVID-19 infections in patients receiving dialysis due to end-stage kidney disease. The study included 189 participants in the United States. The results are now available and could provide new ways to protect this vulnerable group from infections, improving their safety during the ongoing pandemic.

Optimizing Access Surgery In Senior Hemodialysis Patients

This study looked at different types of vascular access surgery for older adults on hemodialysis, which is a treatment to clean the blood when the kidneys are not working. The goal was to find the best methods to improve quality of life and reduce complications related to dialysis access. Conducted in the Netherlands with 166 participants, the results will help doctors and patients make better-informed decisions about dialysis access surgery in senior patients.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.